Navigation Links
High-trauma fractures in older men and women linked to osteoporosis
Date:11/28/2007

High-Trauma Fractures in Older Men and Women Linked to Osteoporosis Researchers at the California Pacific Medical Center (CPMC) Research Institute are challenging a widely held belief that fractures resulting from major trauma, such as automobile accidents, are not related to osteoporosis, the common disease that makes bones weak and prone to fracture. Their study, published in the November 28 issue of the Journal of the American Medical Association, was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the National Institute on Aging (NIA). NIAMS and NIA are components of the National Institutes of Health.

People with osteoporosis, a condition of low bone mineral density, experience fractures from a level of force that would not break a healthy bone. Although clinicians often recognize fractures resulting from minimal trauma as osteoporotic, those related to more substantial injury are rarely given the same consideration. "We know that too many clinicians pass on any follow-up of many fracture patients because, in their minds, the patient earned their fracture," says Joan A. McGowan, Ph.D., director of the Division of Musculoskeletal Diseases at NIAMS. "These missed opportunities can have a devastating impact on these men and women, who, without proper management, are at increased risk for subsequent fracture."

CPMCs Steven R. Cummings, M.D., and his colleagues analyzed data from two large prospective cohort studies: the Study of Osteoporotic Fractures (SOF) in women and the Osteoporotic Fractures in Men Study (Mr. OS). The SOF followed 8,022 women for nine years and Mr. OS tracked 5,995 men for five years. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry (DXA). Study participants were contacted every four months to determine whether they experienced a fracture in the previous four-month period.

When a fracture was reported, clinical staff interviewed the
'/>"/>

Contact: Trish Reynolds
reynoldsp2@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. High-Trauma Fractures Tied to Weak Bones
2. Engineers developing new cements to heal spinal fractures
3. Ability to cope with stress can increase good cholesterol in older white men, study finds
4. Many Older Americans Have Active Sex Lives
5. Good Cholesterol Wont Help Heavy-Drinking Older Men
6. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
7. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
8. Manor Care, Inc. Announces Change of Location for Special Stockholder Meeting
9. Frequent alcohol consumption increases cancer risk in older women
10. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
11. ISS and Glass Lewis Recommend Cholestech Stockholders Vote FOR Merger
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3Health News:Betty White's Video States Support for Funding Humane Research to Help Pets and Wild Animals - Actress is 40-Year Champion of Morris Animal Foundation 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Playing Video Games May Boost Older Brains 2Health News:Playing Video Games May Boost Older Brains 3Health News:Cancer drugs in the pipeline 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 1SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 2SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 3SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 4SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 5SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 6African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 1African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 2African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 3African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 4Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2